The government will negotiate new prices for the commonly prescribed drugs, but the cuts won't take effect until 2026. In the meantime, drug makers are fighting the negotiations with lawsuits.
, as are Enbrel and Stelara, drugs used to treat autoimmune diseases like rheumatoid arthritis, psoriasis and Crohn's disease. Imbruvica, a drug that treats blood cancers, is also on the list.
Drug makers have said the new provisions are unconstitutional and have filed a series of lawsuits to try to stop them. Lobby group Pharmaceutical Research and Manufacturers of America said the change gives the government too much power and would hurt the innovation and investment needed for Biden administration's push to end cancer."Today's announcement is the result of a rushed process focused on short-term political gain rather than what is best for patients," PhRMA CEO Stephen Ubl said in a statement.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Judge rejects Trump bid to push federal election trial to 2026Special counsel Jack Smith has proposed taking the case to trial early next year, while Trump's lawyers argued that it should be held in spring of 2026.
Leer más »
Trump’s Trial on Election Interference Can’t Wait Until 2026, Federal Judge SaysFederal Judge Tanya Chutkan denied a delay request, but hasn’t yet ruled on when the trial will start.
Leer más »
Why Avengers 5 Was Delayed ExplainedFrom 2025 to 2026.
Leer más »
US to name first 10 drugs for Medicare price negotiationThe Biden administration on Tuesday is expected to release its list of 10 prescription medicines that will be subject to the first-ever price negotiations by the U.S. Medicare health program that covers 66 million people.
Leer más »
US government names first 10 drugs for Medicare price negotiationThe Biden administration on Tuesday released its list of 10 prescription medicines including blood thinner Eliquis from Bristol Myers Squibb and Pfizer that will be subject to the first-ever price negotiations by the Medicare health program.
Leer más »